Abstract
BackgroundLong non-coding RNAs play an important role in breast cancer. Even with adjuvant hormone therapy, patients with estrogen receptor positive breast cancer can present with recurrences and distant metastases. We investigated whether the expression of a novel long non-coding RNA LINC00309 can predict the outcome of breast cancer, especially for hormone-receptor positive patients.MethodsThis retrospective study collected 290 breast cancer patients including 161 patients with hormone-positive. qPCR was performed to detect the expression of LINC00309. Kaplan–Meier and Cox risk proportion model were applied to disclose the function of LINC00309 for breast cancer prognosis.ResultsLINC00309 high expression was an independent predictor for worse disease-free survival (HR = 2.127; 95% CI 1.074–4.212; p = 0.030) and associated with a shorter disease-free survival (p = 0.027), especially in hormone-positive breast cancer patients (p = 0.001). Also LINC00309 high expression was associated with a shorter disease-free survival both in selective estrogen receptor modulator related hormone therapy (p = 0.025) and aromatase inhibitors related hormone therapy (p = 0.048). Moreover, LINC00309 was an independent predictor of worse disease-free survival in hormone-receptor positive breast cancer patients on univariate (HR = 4.505; 95% CI 1.722–11.785; p = 0.002) and multivariate (HR = 4.159; 95% CI 1.537–11.251; p = 0.005) analyses.ConclusionIn breast cancer, Linc00309 is significantly associated with poor prognosis and may represent a new marker of prognosis.
Highlights
Long non-coding ribonucleic acid (RNA) play an important role in breast cancer
According to disease free survival (DFS) receiver operating characteristic (ROC) curve, 112 cases were in LINC00309 low group, and the other 178 cases were in the LINC00309 high group
LINC00309 high expression was an independent poor predictor for DFS Breast cancer (BC) based on both univariate (HR = 1.990; 95% confidence interval (CI) 1.069– 3.703; p = 0.030) and adjusted multivariate survival analyses (HR = 2.127; 95% CI 1.074–4.212; p = 0.030) (Table 1)
Summary
Long non-coding RNAs play an important role in breast cancer. Even with adjuvant hormone therapy, patients with estrogen receptor positive breast cancer can present with recurrences and distant metastases. We investigated whether the expression of a novel long non-coding RNA LINC00309 can predict the outcome of breast cancer, especially for hormone-receptor positive patients. Hormone-receptor (HR) positive BC is the largest therapeutic subtype of the disease, accounting for 60% to 75% of all the kinds’ of the malignant neoplasm breast disease [2]. Long non-coding RNAs (lncRNAs) are generated through PCGs similar pathways, with similar histone-modification profiles, splicing signals, and exon/intron lengths [5]. They have key roles in diverse biological processes, and their interfacing with epigenetic regulatory pathways resulted in emerging scientific interest [6, 7].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
